Zalcitabine
Hivid (zalcitabine) is a small molecule pharmaceutical. Zalcitabine was first approved as Hivid on 1992-06-19. It is used to treat acquired immunodeficiency syndrome in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| infections | D007239 |
| urogenital diseases | D000091642 |
| immune system diseases | D007154 |
Trade Name
FDA
EMA
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| acquired immunodeficiency syndrome | EFO_0000765 | D000163 | B20 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
75 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hiv infections | D015658 | EFO_0000764 | B20 | 6 | 18 | 10 | 3 | 9 | 45 |
| Parkinson disease | D010300 | EFO_0002508 | G20 | 5 | 6 | 4 | 2 | 2 | 18 |
| Acquired immunodeficiency syndrome | D000163 | EFO_0000765 | B20 | 1 | 8 | 3 | 1 | 4 | 17 |
| Lipodystrophy | D008060 | HP_0009125 | E88.1 | — | — | — | 2 | — | 2 |
| Hemophilia a | D006467 | EFO_0007267 | D66 | — | — | — | 1 | — | 1 |
| Acidosis | D000138 | EFO_1000014 | E87.2 | — | — | — | 1 | — | 1 |
| Lactic acidosis | D000140 | HP_0003128 | E87.20 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Infections | D007239 | EFO_0000544 | — | 1 | 6 | 3 | — | 2 | 12 |
| Communicable diseases | D003141 | — | — | 1 | 5 | 2 | — | 1 | 9 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Central nervous system diseases | D002493 | HP_0002011 | G96.9 | 1 | 2 | — | — | — | 3 |
| Brain diseases | D001927 | HP_0001298 | G93.40 | 1 | 2 | — | — | — | 3 |
| Nervous system diseases | D009422 | — | G00-G99 | 1 | 2 | — | — | — | 3 |
| Movement disorders | D009069 | HP_0100022 | — | 1 | 2 | — | — | — | 3 |
| Neurodegenerative diseases | D019636 | EFO_0005772 | G31.9 | 1 | 2 | — | — | — | 3 |
| Disease progression | D018450 | — | — | — | 2 | — | — | — | 2 |
| Dyskinesias | D020820 | HP_0002310 | G24 | — | 1 | — | — | — | 1 |
| Leukoencephalopathies | D056784 | HP_0002352 | — | — | 1 | — | — | — | 1 |
| Progressive multifocal leukoencephalopathy | D007968 | EFO_0007455 | A81.2 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Aids-related complex | D000386 | EFO_0007137 | B20 | 1 | — | — | — | 1 | 2 |
| Inborn errors amino acid metabolism | D000592 | — | E72.9 | 1 | — | — | — | 1 | 2 |
| Hepatitis c | D006526 | — | B19.2 | 1 | — | — | — | — | 1 |
| Hepatitis | D006505 | HP_0012115 | K75.9 | 1 | — | — | — | — | 1 |
| Hepatitis a | D006506 | EFO_0007305 | B15 | 1 | — | — | — | — | 1 |
| Parkinsonian disorders | D020734 | HP_0001300 | G20.C | 1 | — | — | — | — | 1 |
| Basal ganglia diseases | D001480 | HP_0002134 | — | 1 | — | — | — | — | 1 |
| Sarcoma | D012509 | — | — | 1 | — | — | — | — | 1 |
| Kaposi sarcoma | D012514 | — | C46 | 1 | — | — | — | — | 1 |
| Argininosuccinic aciduria | D056807 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Multiple myeloma | D009101 | — | C90.0 | — | — | — | — | 1 | 1 |
| Plasma cell neoplasms | D054219 | — | — | — | — | — | — | 1 | 1 |
| Hypoxia | D000860 | HP_0012418 | R09.02 | — | — | — | — | 1 | 1 |
| Virus diseases | D014777 | — | B34 | — | — | — | — | 1 | 1 |
| Immunologic deficiency syndromes | D007153 | HP_0002721 | D84.9 | — | — | — | — | 1 | 1 |
| Keratitis | D007634 | HP_0000491 | H16 | — | — | — | — | 1 | 1 |
| Autoimmune hepatitis | D019693 | — | — | — | — | — | — | 1 | 1 |
| Syndrome | D013577 | — | — | — | — | — | — | 1 | 1 |
| Autoimmune polyendocrinopathies | D016884 | — | E31.0 | — | — | — | — | 1 | 1 |
| Pancreatitis | D010195 | HP_0001733 | K85 | — | — | — | — | 1 | 1 |
Show 5 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Zalcitabine |
| INN | zalcitabine |
| Description | Zalcitabine is a pyrimidine 2',3'-dideoxyribonucleoside compound having cytosine as the nucleobase. It has a role as an antiviral drug, an antimetabolite and a HIV-1 reverse transcriptase inhibitor. |
| Classification | Small molecule |
| Drug class | nucleoside antiviral or antineoplastic agents, cytarabine or azarabine derivatives |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | Nc1ccn([C@H]2CC[C@@H](CO)O2)c(=O)n1 |
Identifiers
| PDB | — |
| CAS-ID | 7481-89-2 |
| RxCUI | — |
| ChEMBL ID | CHEMBL853 |
| ChEBI ID | 10101 |
| PubChem CID | 24066 |
| DrugBank | DB00943 |
| UNII ID | 6L3XT8CB3I (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 3,545 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
243 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use